Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reached a new 52-week high during trading on Friday . The stock traded as high as $88.70 and last traded at $88.45, with a volume of 342,285 shares. The stock had previously closed at $85.73.

A number of equities research analysts have issued reports on the company. Vetr lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target for the company. in a research note on Monday, May 15th. Zacks Investment Research upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 price target for the company in a research note on Wednesday, July 12th. Cowen and Company reiterated an “outperform” rating and issued a $100.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, May 17th. Credit Suisse Group reiterated a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 9th. Finally, Chardan Capital cut their price target on Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $81.74.

The stock has a 50 day moving average of $81.77 and a 200 day moving average of $66.47. The stock’s market capitalization is $8.16 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same period last year, the company earned ($1.05) EPS. The business’s quarterly revenue was up 82.9% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.21) EPS for the current year.

Several institutional investors have recently modified their holdings of ALNY. BlackRock Inc. raised its position in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares in the last quarter. Perceptive Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares in the last quarter. FMR LLC raised its position in shares of Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $53,226,000. Hedge funds and other institutional investors own 94.27% of the company’s stock.

WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Sets New 52-Week High at $88.70” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/02/alnylam-pharmaceuticals-inc-alny-sets-new-52-week-high-at-88-70.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).